Stayble Therapeutics AB (publ)
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a STABL.ST research report →
Companywww.staybletherapeutics.se
Stayble Therapeutics AB (publ) develops injectable treatment for chronic low back pain triggered by disc degeneration. The company develops STA363, a minimally invasive single injection of the drug into the disc that targets chronic low back pain. Stayble Therapeutics AB (publ) was incorporated in 2015 and is based in Gothenburg, Sweden.
- CEO
- Andreas Gerward
- IPO
- 2020
- Employees
- 2
- HQ
- Gothenburg, SE
Price Chart
Valuation
- Market Cap
- $14.22M
- P/E
- -2.05
- P/S
- 646.52
- P/B
- 2.05
- EV/EBITDA
- -2.33
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 100.00%
- Op Margin
- -14563.64%
- Net Margin
- -31490.91%
- ROE
- -84.80%
- ROIC
- -41.22%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-6,928,000 · 44.21%
- EPS
- $-0.12 · 63.64%
- Op Income
- $-6,896,000
- FCF YoY
- 100.00%
Performance & Tape
- 52W High
- $0.65
- 52W Low
- $0.03
- 50D MA
- $0.16
- 200D MA
- $0.22
- Beta
- -0.88
- Avg Volume
- 3.33M
Get TickerSpark's AI analysis on STABL.ST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our STABL.ST Coverage
We haven't published any research on STABL.ST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate STABL.ST Report →